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Paeoniflorin inhibits the growth of bladder carcinoma 
via deactivation of STAT3
Bladder cancer (BCa) is one of the most common urinary 
cancers. The present study aims to investigate whether Pae-
oniflorin (Pae) can exert inhibitory effects on BCa. The re-
sults showed that Pae inhibited proliferation of human BCa 
cell lines in a concentration- and time-dependent manner. 
Pae and cisplatin (Cis) synergistically inhibited the growth 
of tumours in RT4-bearing mice. Pae treatment neutralized 
the body loss induced by Cis. Moreover, Pae induced apop-
tosis in RT4 cells and increased the activities of caspase3, 
caspase8 and caspase9. Western blotting and immunohisto-
chemical analysis revealed that the phosphorylated signal 
transducer and activator of transcription-3 (p-STAT3) level 
were decreased in Pae-treated RT4 cells and Pae-treated 
tumour-bearing mice. Furthermore, STAT3 transcriptional 
target B-cell lymphoma-2 was decreased in Pae-treated RT4 
cells. Interestingly, Pae prevented translocation of STAT3 to 
the nucleus in RT4 cells. Collectively, Pae inhibits the growth 
of BCa, at least in part, via a STAT3 pathway.
Keywords: bladder cancer, Radix Paeoniae alba, paeoniflorin, 
apoptosis, STAT3
Bladder cancer (BCa) is one of the most common malignancies in the western world. 
In the United States, it was estimated that there were 76,960 new cases and 16,390 deaths 
in 2016 (1). It was previously reported that approximately 30 % of BCa patients had muscle 
and invasive cancer cells and 10 % of patients suffered from metastatic disease, which re-
sulted in a poor prognosis (2). Current application of chemotherapy, radiotherapy and 
 radiochemotherapy has made great progress in preventing BCa, and the overall survival 
has been improved. However, recurrence and metastasis of BCa occurs frequently, leading 
to unsatisfactory survival rates. Moreover, poor prognosis has persisted due to fatigue, 
pain and side effects induced by chemotherapy (3). Thus, there is a demand to develop a 
safe and effective drug for improving treatment and prognosis of BCa patients.
Signal transducer and activator of transcription-3 (STAT3), one of the STAT family mem-
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lowing activation, phosphorylated STAT3 (p-STAT3) dimerizes and translocates to the nucleus, 
where it finally regulates the expression of numerous critical genes that control cell pro-
liferation and survival (5–6). A number of studies have been performed on BCa, which have 
highlighted STAT3 as a potential therapeutic target. In clinical specimens, it has been con-
firmed that urothelial BCa displays elevated expression as well as activation of STAT3 (7). 
Silencing of STAT3 suppresses the proliferation of T24 cells in vitro and in vivo compared to 
the controls, and overexpression of STAT3 prevents cells from undergoing morphological 
changes and apoptosis triggered by the Ha-ras oncogene (8–9). Moreover, inhibition of STAT3 
by small interfering RNA or a specific inhibitor restores chemosensitivity in T24 cells (10), 
suggesting that STAT3 could be a major target for increasing chemosensitivity in patients.
Interest in the identification of novel anticancer agents derived from natural sources 
has been growing exponentially. Paeoniflorin (Pae) is the main active ingredient of Radix 
Paeoniae alba (RPA), which is used in traditional Chinese medicine to treat a range of in-
flammatory diseases (11). Today, there is interest in studying the therapeutic effects of Pae 
on different cancer types. In previous pharmacological investigations, Pae was confirmed 
to inhibit the growth of human pancreatic cancer, gastric carcinoma cells, colorectal carci-
noma cells, and glioma cells (12–15). A new study (16) recently reported the anti-prolifera-
tive properties of RPA extraction in treating BCa, both in vitro and in vivo. However, it is 
unknown whether Pae could inhibit BCa. Therefore, the main purpose of the present 
study was to estimate the anti-tumour activity of Pae in BCa.
EXPERIMENTAL
Cell lines and culture
Human BCa cell lines (RT4, 253J and J82) were originally obtained from the American 
Type Culture Collection (Manassas, VA, USA). The cells were maintained in Dulbecco’s 
Modified Eagle Medium (Gibco-BRL, USA), supplemented with 10 % foetal bovine serum 
(Sigma-Aldrich, USA), 4 mmol L–1 glutamine and 100 U mL–1 penicillin, at 37 °C in 5 % CO2.
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay
A total of 2 × 103 cells were seeded in a 96-well plate and then incubated with different 
concentrations of Pae (purity > 98 %; Chengdu Biopurify Phytochemicals Ltd., China) for 
24–72 h. The cells were treated with 20 µL of MTT (5 g L–1, Sigma-Aldrich) solution and in-
cubated at 37 °C for 4 h. After discarding the medium, absorbance was recorded by a micro-
plate reader (Biotek, Vermont, USA). Each cell viability assay was performed in triplicate. 
The relative cell viability (%) was determined by comparing the absorbance with the control, 
which was treated with a phosphate buffered solution (PBS). The IC50 value was determined 
according to the growth curve of the cells using the GraphPad Prism 5.0 software.
Apoptosis assay
Apoptosis in RT4 cells was detected using a cell apoptosis detection kit (BD Pharmin-
gen, San Diego, CA, USA). Briefly, the cells were seeded 2.5 × 105 per well in 6-well plates 
for 24 h and were then treated with Pae (25 or 50 µM) for 48 h. The cells were labelled by 
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Annexin V-fluorescein isothiocyanate (FITC) and stained using a binding buffer for 30 min 
in the dark according to the instructions. Subsequently, 10 µL of propidium iodide (PI) was 
added to the cells and incubated for 15 min at room temperature in the dark. The apoptotic 
rate was measured by flow cytometry (FACS Calibur, BD Biosciences).
Caspase activity assay
Activities of caspase-3, caspase-8 and caspase-9 in Pae-treated RT4 cells (48 h) were 
detected by caspase activity assay kits from Beyotime Biotechnology (China).
Western blotting
RT4 cells were pre-treated with Pae (25 or 50 µM) in a serum-free medium for 48 h. 
Nuclear protein was extracted using a nuclear and cytoplasmic protein extraction kit pro-
vided by Beyotime Biotechnology (Nantong, China). The amount of protein was quantified 
by the bicinchoninic acid assay (Thermo Fisher Scientific, USA). Equal amounts of extract 
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene difluoride membranes (Gibco-Life Technologies, USA). The mem-
branes were incubated with a primary antibody and then probed with a secondary anti-
body and visualized by enhanced chemiluminescence. All western blot experiments were 
performed at least three times. The primary antibodies used were as follows: anti-B-cell 
lymphoma-2 (Bcl-2), anti-Bcl-2 associated X protein (Bax) and anti-p-STAT3, all purchased 
from Santa Cruz Biotechnology (USA). β-actin and histone were used as internal controls 
for relative quantification.
In vivo tumour xenograft study
Male BALB/c nude mice (20–22 g) were from the Shanghai Laboratory Animal Center 
Co., Ltd. (China). The animals were housed in temperature-controlled rooms (22 ± 2 °C), 
with relative humidity of 55 ± 5 % and a 12 h light/dark cycle. All protocols involved in 
animal experiments were approved by the Animal Care and Use Committee of Ningbo 
Urology and Nephrology Hospital (Qianhe road, No. 1, Yinzhou, Ningbo, China). More-
over, the animal experiments were also conducted according to the U.K. Animals (Scien-
tific Procedures) Act, of 1986 and associated guidelines. RT4 cells (5 × 106) in 100 µL of PBS 
were subcutaneously injected into the right flank area of the mice. After the tumours grew 
to an area of about 100 mm3, the tumour-bearing mice were randomly divided into the 
control group, Pae group (purity > 98 %, 100 mg kg–1, Aladdin Ltd.), cisplatin (Cis, purity > 
99 %, 5 mg kg–1, Sigma-Aldrich,) group, and Pae (100 mg kg–1) + Cis (5 mg kg–1) group, with 
five mice in each group. They were given an intraperitoneal injection daily for 20 days. 
Body weight and tumour growth were measured every four days. The size of tumours was 
measured according to the following formula: tumour volume = π/6 × L × W2, in which L 
and W represent the major and minor diameter, respectively. At the end of the study, the 
mice were sacrificed and tumour tissue was weighed prior to immunohistochemistry.
Immunohistochemistry and immunocytochemistry
RT4 cells were treated with 50 µM Pae for 48 h and fixed in 4 % paraformaldehyde for 
20 min at room temperature. The cells were incubated with anti-STAT3 overnight at 4 °C 
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(1:100, Santa Cruz), followed by incubation with FITC-conjugated secondary antibodies for 
1 h at room temperature. Finally, the cells were labelled with a 4’,6-diamidino-2-phenylin-
dole (DAPI) solution and observed with a confocal laser scanning microscope (TCS SP8, 
Leica Microsystems, Germany). Moreover, tumour tissues were fixed with 10 % formalde-
hyde for 24 h. Paraffin-embedded slides were conventionally prepared. The sections were 
deparaffinised in xylene, rehydrated by descending grades of ethanol, and incubated with 
an antibody against p-STAT3 (Santa Cruz Biotechnology). After washing with PBS, slides 
were incubated with the biotinylated secondary antibody (Dako). The immunostained 
cells were quantified by counting the brown cells and the total number of cells in five 
randomly selected fields at 400× magnification.
Statistical analysis
The data are expressed as the mean ± SD. The statistical difference was determined by 
one-way ANOVA tests and Student’s t-test. A P value less than 0.05 was considered statis-
tically significant. All statistical analyses were performed using the SPSS version 13.0 sta-
tistical software (SPSS, USA).
RESULTS AND DISCUSSION
The cytotoxic effect of Pae on BCa cells was evaluated by the MTT assay after expo-
sure to Pae. As shown in Fig. 1b,c, Pae treatment decreased RT4, J82 and 253J cell viability 
Fig. 1. Cytotoxicity of Pae in 
BCa cells. a) Pae chemical 
structure, b) RT4 cells were 
incubated with different 
concentrations of Pae for 24, 
48 and 96 h, c) IC50 of Pae. 
Data are presented as the 
mean ± SD, n = 3; b p < 0.01 
compared to the 96 h group.
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in a dose-dependent and time-dependent manner. The IC50 values of Pae in the RT4 group 
were lower than that in J82 and 253J cells (p < 0.01). Consequently, RT4 was used for the 
following study.
We further examined whether Pae could induce apoptosis in RT4 cells. As seen in 
Fig. 2, Pae treatment induced total apoptosis in RT4 cells. Moreover, we also noticed that 
Pae-treated RT4 cells showed higher levels of early and late apoptotic rates compared to 
those of the control group (p < 0.01, Table I). To determine the mechanism underlying the 
Pae-mediated apoptosis in RT4 cells, we investigated the effects on caspase3, caspase8 and 
caspase9 activities. The results showed that Pae treatment increased the activities of 
caspase3, caspase8 and caspase9 in RT4 cells (p < 0.01, Table II). Moreover, it should be 
noted that Bax expression increased and Bcl-2 expression decreased in RT4 cells that were 
exposed to Pae (p < 0.01, Fig. 3a,b).
As STAT3 plays an important role in BCa cell proliferation and survival, we investi-
gated whether Pae modulates constitutive STAT3 activation in RT4 cells. Fig. 4A-4B show 
Fig. 2. Effects of Pae on apoptosis of RT4 cells. a) Representative apoptosis data analysed by flow cyto-
metry using an AnnexinV-FITC in RT4 cells are shown for a1 (control group), a2 (Pae 25 µM group) and 
a3 (Pae 50 µM group), b) quantitative apoptosis data in Pae treated RT4 cells are shown. Data are pre-
sented as the mean ± SD, n = 3; **p < 0.01 compared to the control group (without Pae treatment).
a1                                                                     a3
 
a2                                                                    b)
           a)
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that Pae incubation inhibited STAT3 phosphorylation in RT4 cells (p < 0.01). Moreover, in 
view of the nuclear translocation of STAT3 being central to the biological function, we 
determined whether Pae suppressed nuclear translocation of STAT3. As shown in Fig. 4c, 
Pae treatment inhibited the translocation of STAT3 to the nucleus in RT4 cells.
To determine if Pae could inhibit tumour growth in vivo, we studied the effects of Pae 
on RT4 cell xenografts in nude mice. As shown in Fig. 5B-5C, administration of Pae sig-
nificantly reduced the weight and volume of tumour tissue (p < 0.01). Interestingly, we 
noticed that Pae and Cis showed synergistically inhibitory effects on the growth of tumour 
Fig. 3. Effects of Pae on Bax and Bcl-2 levels. a) Representative immunoblotting bands of Bax and Bcl-2. 
β-actin was used as an internal reference, b) quantitative data of the levels of Bax and Bcl-2. Data are 
presented as the mean ± SD, n = 3; ** p < 0.01 compared to the control group (without Pae treatment).
Table I. Effects of Pae on early and late apoptosis of RT4 cells
Concentration (µM) Early apoptosis (%) Late apoptosis (%)
0 1.88 ± 0.26 5.20 ± 0.62
25 3.07 ± 0.34** 9.50 ± 0.52**
50 8.45 ± 0.41** 18.20 ± 1.30**
Data are presented as the mean ± SD, n = 3; **p < 0.01 compared to the control group (without Pae treatment).
Table II. Effects of Pae on caspase activities of RT4 cells
Concentration (µM) Caspase-3 activity (IU) Caspase-8 activity (IU) Caspase-9 activity (IU)
0 1.88 ± 0.26a 1.51 ± 0.16 2.20 ± 0.41
25 4.62 ± 0.50b 6.90 ± 0.75b 5.08 ± 0.52b
50 12.2 ± 0.92b 8.56 ± 0.56b 11.50 ± 3.73b
Data presented as the mean ± SD, n = 3; bp < 0.01 compared to the control group (without Pae treatment).
a)                                                                    b)
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tissue (p < 0.01). In addition, Pae treatment had no effects on the body mass of tumour-
bearing mice, while Cis significantly reduced the weight (Fig. 5a, p < 0.01). Furthermore, 
the body weight of the combined group was not statistically different from that of the 
control group and the Pae group at the end of the study. Moreover, in Fig. 5d, the rates of 
p-STAT3-positive cells in control or Pae-treated mice were 46.0 ± 4.5 % and 12.0 ± 1.3 %, 
respectively (p < 0.01), suggesting that Pae significantly suppresses the activation of STAT3 
in RT4-bearing mice.
Naturally derived compounds are a prime source of highly effective conventional 
anti-cancer drugs. Pae, extracted from RPA, is a natural anti-cancer medicine. Many phar-
macological studies have reported that Pae exerts anti-cancer and anti-proliferative activity 
in cultured tumour cells, as well as in tumour xenograft models (12–15). In 2016, Lin et al. 
(16) reported the anti-proliferative properties of RPA extract on BCa, both in vitro and in 
vivo. In their research, they also found that the extract showed lower cytotoxicity to normal 
cells compared to that in BCa cells. It is well known that Pae is the main active ingredient 
in the RPA extract (17). Therefore, the evidence suggests that Pae may inhibit the growth 
of BCa tumours. Our investigation first explored the anti-tumour effects of Pae in BCa in 
both in vitro and in vivo models. Our data demonstrated that Pae effectively inhibits BCa 
cell (RT4, J82 and 253J) growth in vitro. The IC50 of Pae for inhibiting RT4 growth is 88.93 
µM, which is similar to previous studies conducted in BxPC-3 cells (12). In the in vivo study, 
we observed that oral administration of Pae significantly inhibited tumour growth and 
that Pae & Cis showed synergistically inhibitory effects on the growth of tumours. Some 
Fig. 4. Effects of Pae on p-STAT3 expression and nuclear translocation in vitro. a) Representative im-
munoblotting bands of p-STAT3. Histone was used as an internal reference, b) quantitative data of 
p-STAT3 expression, c) RT4 cells were treated with 50 µM Pae for 48 h. Data are presented as the mean 
± SD, n = 3; ** p < 0.01 compared to the control group (without Pae treatment).
a)                                                                                  c)
b)
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previously published papers have shown similar results. For instance, in 2008, Wu et al. 
(18) reported that Pae enhanced 5-fluorouracil-induced apoptosis in human gastric carci-
noma cells, and Fang et al. (19) concluded that Pae at non-toxic concentrations effectively 
modulated multidrug resistance of a human gastric cancer cell line via inhibition of nucle-
ar factor-kappa B activation. Similarly, Hao et al. (12) previously confirmed that Pae enhanced 
the effect of erlotinib in pancreatic cancer cells by directly suppressing human epidermal 
growth factor receptor-3 activation. Based on these findings, we may speculate that Pae 
has a synergistic effect with chemotherapeutic drugs regarding the molecular mechanisms 
or intracellular pharmacokinetic processes. An unexpected finding in the present study 
was that Pae had no effect on body weight but neutralized body mass loss induced by Cis. 
These interesting results may be explained as follows: Pae shows high selectivity with an 
anti-tumour dose and inhibits the growth of tumour cells rather than normal cells. It was 
shown in a previous study that Pae used against human colon carcinoma in a xenograft 
tumour did not lead to body weight loss or alterations in food consumption, while docetaxel 
resulted in a 23.6 ± 3.1 % mass loss during the same time (20). Moreover, Pae did not show 
any effects on the numbers of leukocytes, erythrocytes and haemoglobin, while docetaxel 
significantly reduced those of leukocytes (20), indicating the safety of Pae. Moreover, Pae 
shows favourable dual immunomodulatory effects and normalizes the function of the 
immune system in various disease states. For example, Pae was shown to enhance and 
Fig. 5. Effects of Pae on tumour growth in RT4 xenograft mice. a) Body mass, b) tumour volume, 
c) tumour mass, d) tumour tissues from the control (d1) and Pae group (d2) were stained with pSTAT3 
antibody. Representative images were recorded at a magnification of 400×, and quantification of the 
immunohistochemical assay is presented as the percentage of positively stained cells in d3. Data are 
presented as the mean ± SD, n = 5; *p < 0.05, **p < 0.01 compared to the control group; ##p < 0.01 com-
pared to the Pae group; NS: No significance.
a)                                                   b)                                                 c)
 
 
d)     d1                                                        d2                                                          d3
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inhibit spleen lymphocyte proliferation at different concentrations (21). Unlike Pae, it is 
well known that Cis can attack and destroy the growth of tumour cells and immune cells 
simultaneously. In addition, Pae attenuated Cis-induced body loss in tumour-bearing 
mice, indicating that Pae reduced chemotherapy -induced toxicity to the immune system. 
In previous investigations, Pae was shown to decrease myelosuppression induced by 
chemotherapy (22). We suspect that Pae could increase the defensive power of the immune 
system in response to chemotherapy. These results indicate that Pae is a potential anti-
tumour adjuvant in the prevention of BCa development.
Apoptosis is a process of programmed cell death. In general, two major apoptotic 
pathways have been described for mammalian cells. The first pathway, called the extrinsic 
pathway, is characterized by activation of caspase-8. The second pathway, called the in-
trinsic pathway, is characterized by activation of caspase-9. Activation of caspase-8 and 
caspase-9 could trigger activation of the downstream caspase-3. Moreover, the intrinsic 
pathway is also modulated by Bcl-2 family members, which play key regulatory roles in 
apoptosis (23–24). In previous studies, Pae induced apoptosis in several types of tumour 
cells with activation of caspases. For instance, Wang et al. (14) reported that Pae induced 
apoptosis in HT 29 cells and activated caspase-3 and caspase-8. Wang et al. (25) found that 
Pae effectively increased cell apoptosis and augmented the activation of caspase-3 and 
caspase-9 in SKO-007 cells. In our study, we found that induction of apoptosis was ob-
served in RT4 cells exposed to Pae, followed by activation of caspase-3, caspase-8 and 
caspase-9. Furthermore, Pae also increased the level of Bax and simultaneously reduced 
the level of Bcl-2. These results demonstrated that both the extrinsic and intrinsic path-
ways seemed to be engaged in the Pae-treated RT4 cell types, which is in agreement with 
previously published results.
Many studies have been conducted to reveal the mechanisms of the Pae anti-tumour 
action. Some previous studies reported that Pae exerted its anti-tumour activity via sup-
pressing extracellular regulated protein kinases and phosphatidylinositol 3-kinase/pro-
tein kinase B signalling pathways (26–27). Moreover, other studies concluded that Pae in-
duced apoptosis in hepatocellular carcinoma cells by down-regulating prostaglandin E 
receptor 2 (28). It is accepted that the STAT3 signalling pathway is over-activated and 
contributes to tumour progression in malignancies. Constitutive activation of STAT3 re-
sulted in cell growth and survival in human solid tumour malignancies and the up-regu-
lation of anti-apoptotic proteins (Bcl-2, Survivin) (29–30). Therefore, deactivation of STAT3 
is associated with the induction of apoptosis and conveyance of anti-tumour effects. In 
2015, Zheng et al. (15) demonstrated that Pae significantly inhibited total expression of p-
STAT3 in MGC-803 cells and that over-expression of STAT3 reversed the effect of Pae on 
the proliferation of MGC-803. As the tumour-promoting effects are ultimately regulated 
by the STAT3-dependent transcriptional regulation of downstream oncogenes, we focused 
on the nuclear level of p-STAT3. Our results showed that Pae reduced the expression of 
nuclear p-STAT3 and demonstrated that Pae also decreased p-STAT3-positive cells num-
bers in vivo. As expected, we also found that Pae inhibited translocation of STAT3 to the 
nucleus in RT4 cells. It is noteworthy that a recent study conducted by Nie et al. (13) found 
rapid down-regulation of STAT3 that was consistent with its accelerated degradation, and 
the pro-degradation effect of Pae on STAT3 was mainly through the ubiquitin-proteasome 
pathway. Therefore, these findings clearly indicate that deactivation of STAT3 by Pae con-
tributes to its inhibitory effects on BCa development.
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CONCLUSIONS
The present study demonstrated that Pae caused growth inhibition in human BCa 
cells, both in vivo and in vitro. To the best of our knowledge, our data support the hypoth-
esis that Pae may be an effective anti-tumour agent for the treatment of human BCa. Its 
action is regulated, at least in part, by deactivation of STAT3 and inhibition of subsequent 
nuclear translocation.
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